Hookipa Pharma (HOOK) Set to Announce Earnings on Thursday

Hookipa Pharma (NASDAQ:HOOK) is scheduled to be announcing its earnings results before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.12) per share for the quarter.

Hookipa Pharma (NASDAQ:HOOK) last posted its quarterly earnings data on Friday, March 22nd. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. Hookipa Pharma had a negative return on equity of 72.30% and a negative net margin of 405.28%. The company had revenue of $7.41 million during the quarter, compared to analysts’ expectations of $3.60 million. On average, analysts expect Hookipa Pharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Hookipa Pharma Price Performance

Shares of NASDAQ HOOK traded up $0.00 on Wednesday, hitting $0.83. The company’s stock had a trading volume of 15,871 shares, compared to its average volume of 735,149. The stock has a 50 day moving average of $0.78 and a 200-day moving average of $0.68. The company has a market capitalization of $82.13 million, a price-to-earnings ratio of -0.97 and a beta of 0.92. Hookipa Pharma has a 12-month low of $0.41 and a 12-month high of $2.05.

Analyst Ratings Changes

A number of analysts have recently commented on HOOK shares. HC Wainwright dropped their price objective on Hookipa Pharma from $6.50 to $5.00 and set a “buy” rating for the company in a report on Friday, April 26th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $5.00 price target on shares of Hookipa Pharma in a report on Monday, March 25th.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.